Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Making its debut on 02/05/2001, smart beta exchange traded fund iShares Biotechnology ETF (IBB) provides investors broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.
Biotech Breakout: Stocks for Your Watchlist
After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF NASDAQ: IBB, the sector has turned a significant corner, with previous resistance levels becoming support, setting the stage for a potential momentum shift.
3 ETFs for Growth Investors to Buy and Hold for Decades
Exchange-traded funds aren't just for risk-averse investors. Many funds can give exposure to some great growth stocks.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on 02/05/2001.
Key Stock Market ETFs Hanging Tough Amidst Volatility
Here we are, another week and another notch on the bull market belt. Last weekend, we were very bullish coming into this past week on Small Caps, Biotechnology and Regional Banks.
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum
Biotechnology companies experienced an optimistic bullish cycle in 2020-2021, leading to outperformance of the Biotech index. But the cycle of interest rate increases taking place since 2022 has caused several Biotech companies to observe cash flow issues. Advances in AI, machine learning, and generative AI are likely to accelerate drug discovery processes and optimize operations in the biotech and pharma sectors, leading to growth opportunities.
The Biotechnology Sector ETF (IBB) Clears Price Resistance
On June 24, 2024 I wrote a daily called, Biotechnology Sector IBB Breakout Comes To Life: “IBB sits just below the 200-WMA. Plus, he is in the middle of the weekly channel range.
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotechnology sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market, making it one of the worst-performing sectors year-to-date.
